Perioperative anesthesia clinical considerations of alternative medicines

Anesthesiology Clinics of North America

Volumn 22, Issue 1, 2004, Pages 125-139

  Kaye, Alan D ^a,b   Kucera, Ian ^a   Sabar, Raj ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANABOLIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN; DIMENHYDRINATE; ECHINACEA EXTRACT; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; HEPARIN; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; PHOTOSENSITIZING AGENT; PIROXICAM; PLANT EXTRACT; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE; UNINDEXED DRUG; WARFARIN;

ACUPUNCTURE ANALGESIA; ALTERNATIVE MEDICINE; ANESTHESIA; ANXIETY DISORDER; ARTHRALGIA; AUTONOMIC DYSFUNCTION; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BREAST HYPERPLASIA; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM DEPRESSION; CEREBROVASCULAR ACCIDENT; CHINESE MEDICINE; CLINICAL TRIAL; CONSTIPATION; DEATH; DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; DIZZINESS; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFECT; ELECTIVE SURGERY; EPISTAXIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINOSIS; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTENSION; HYPERTHERMIA; HYPHEMA; IMMUNOSTIMULATION; INSOMNIA; INTERMITTENT CLAUDICATION; JOINT STIFFNESS; LIVER TOXICITY; MANIPULATIVE MEDICINE; MASSAGE; MASTALGIA; MEMORY DISORDER; MOTION SICKNESS; MUSCLE HYPERTONIA; MYOCLONUS; NAUSEA; NERVOUSNESS; NEUROTOXICITY; PERIOPERATIVE PERIOD; PHOTOSENSITIVITY; PREOPERATIVE CARE; PSYCHOSIS; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; TACHYCARDIA; THROMBOCYTE AGGREGATION INHIBITION; TINNITUS; TREATMENT OUTCOME; TREMOR; ULCER; VAGINA BLEEDING; VERTIGO; VOMITING; XEROSTOMIA;

ANESTHESIA; ANESTHETICS; AROMATHERAPY; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; HUMANS; NATUROPATHY; PLANTS, MEDICINAL; PREOPERATIVE CARE;

EID: 1942422698     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8537(03)00113-5     Document Type: Review

References (111)

1. Website of National Center for Complementary & Alternative Medicine (NCCAM). Available at www.nccam.nih.gov/health/whatiscam/.
2. Winslow L.C., Kroll D.J. Herbs as medicines. Arch Intern Med. 158:1998;2192-2199.
3. Kleiner S.M. The true nature of herbs. Phys Sportsmed. 23:1995;13-14.
4. Herbal roulette. Consumer reports. Nov 1995: 698-705
5. Kaye A.D., Sabar R., Clarke R., Vig S., Hofbauer R., Kaye A.M. Herbal medications and anesthetics. a review on current concepts. Am J Anesthesiol. 27(8):2000;467-471.
6. Eisenberg D.M., Davis R.B.et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 280:1998;1569-1575.
7. Leak J.A. Herbal Medicine: is it an alternative or an unknown? A brief review of popular herbals used by patients in a pain and symptom management practice setting. Cur Rev Pain. 3:1999;226-236.
8. Brevoort P. The US botanical market: an overview. Herbal Gram. 36:1996;49-57.
9. Ness J., Sherman F.T., Pan C.X. Alternative medicine: what the data say about common herbal therapies. Geriatrics. 54:1999;33-43.
10. Bauer R., Khan I.A., Walter B.et al. Structure and stereochemistry of new sesquiterpene esters from E. purpurea. Helv Chim Acta. 68:1985;2355-2358.
11. Melchart D., Walther E., Linde K.et al. Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled, randomized trial. Arch Fam Med. 7(6):1998;541-545.
12. Grimm W., Muller H.H. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med. 106(2):1999;138-143.
13. Parnham M.J. Benefit-risk assessment of the squeezed sap of the purple coneflower (E. purpurea) for long term oral immunostimulation. Phytomedicine. 3:1996;95-102.
14. Blumenthal M., Gruenwald J.et al. German commission E monographs: therapeutic monographs on medicinal plants. 1998;American Botanical Council, Austin.
15. Miller L.G. Herbal medicinals. Arch InternMed. 158:1998;2200-2211.
16. Eaton E.A., Walle U.K.et al. Flavinoids, potent inhibitors of the human form of phenolsulfotransferase: potential role in drug metabolism and chemoprevention. Drug Met Disp. 24:1996;232-237.
17. Schubert W., Eriksson U.et al. Flavinoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17 beta-estradiol. Eur J Drug Met Pharmaco. 20:1995;219-224.
18. Reuter H.D. Allium sativum and allium ursinum, part 2: pharmacology and medicinal applications. Phytomedicine. 2:1995;73-91.
19. Beaglehole R. Garlic for flavor, not cardioprotection. Lancet. 348:1996;1186-1187.
20. Jain A.K., Vargas R.et al. Can garlic reduce levels of serum lipids? A controlled clinical study. Am J Med. 94(6):1993;632-635.
21. Silagy C.A., Neil H.A.W. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 12:1994;463-468.
22. Neil H.A.W., Silagy C.A.et al. Garlic powder in the treatment of moderate hyperlipidemia: a controlled trial and meta-analysis. J R Coll Physician. 30:1996;329-334.
23. Berthold H.K., Sudhop T., von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trial. JAMA. 279(23):1998;1900-1902.
24. Cooperative group for essential oil of garlic The effect of essential oil of garlic on hyperlipidemia and platelet aggregation: an analysis of 308 cases. J Traditional Chin Med. 6:1986;117-120.
25. Rose K.D., Croissant P.D.et al. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic consumption: a case report. Neurosurgery. 26:1990;880-882.
26. Bordia A. Effect of garlic on human platelet aggregation in vitro. Atherosclerosis. 30:1978;355-360.
27. Grontved A., Hentzer E. Vertigo-reducing effect of ginger root. J Otolaryngol. 48:1986;282-286.
28. Holtmann S., Clarke A.H.et al. The anti-motion sickness mechanism of ginger. Acta Otolaryngol (Stockh). 108:1989;168-174.
29. Fischer-Rasmussen W., Kjaer S.K.et al. Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gyn Rep Biol. 38:1990;19-24.
30. Arfeen Z., Owen H.et al. A double-blind randomized controlled trial of ginger for the prevention of postoperative nausea and vomiting. Anaesth Intensive Care. 23(4):1995;449-452.
31. Visalyaputra S., Petchpaisit N.et al. The efficacy of ginger root in the prevention of postoperative nausea and vomiting after out patient gynecological laparoscopy. Anesthesia. 53(5):1998;506-510.
32. Backon J. Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry. Med Hypoth. 20:1986;271-278.
33. Gillis C.N. Medicinal plants rediscovered. Semin Anesth Periop Med Pain. 17(4):1998;319-330.
34. LeBars P.L., Katz M.M.et al. A placebo controlled, double-blind, randomized trial of an extract of Gingko biloba for dementia. JAMA. 278:1997;1327-1332.
35. Bauer U. Six-month double-blind randomized clinical trial of gingko biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneimittelforschung. 34(6):1984;716-720.
36. Peters H., Kieser M., Holscher U. Demonstration of the efficacy of Gingko biloba special extract EGB 761 on intermittent claudication - a placebo controlled, double-blind multicenter trial. Vasa. 27(2):1998;106-110.
37. Braquet P. BN 52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists isolated from gingko biloba. Blood Vessels. 16:1985;559-572.
38. Braquet P., Bourgain R.H. Anti-anaphylactic properties of BN 52021: a potent platelet activating factor antagonist. Adv Exp Med Biol. 215:1987;215-233.
39. Marcocci L. The nitric oxide scavenging properties of gingko biloba extract Egb761: inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7. Biochem Pharmacol. 53:1997;897-903.
40. Kobuchi H., Ldroy-Lefaix M.T.et al. Gingko biloba extract (Egb 761): inhibitory effect on nitric oxide production in macrophage cell line RAW 264.7. Biochem Pharmacol. 53:1997;897-903.
41. Rosenblatt M., Mindel J. Spontaneous hyphema associated with ingestion of Gingko biloba extract [letter]. N Engl J Med. 336:1997;1108.
42. Rowin J., Lewis S.L. Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion have also occurred. Neurol. 46:1996;1775-1776.
43. Gilbert G.J. Gingko biloba [commentary]. Neurology. 48:1997;1137.
44. Vale S. Subarachnoid hemorrhage associated with Gingko biloba [letter]. Lancet. 352:1998;36.
45. Arenz A., Klien M.et al. Occurrence of neurotoxic 4′-o- methylpyridoxin in gingko biloba leaves, gingko medications and Japanese gingko food. Planta Med. 62:1996;548-551.
46. Lohse M.J., Muller-Oerlinghausen B. Psychopharmaka. Schwabe U., Pffrath D. Arzeiverordnungreport '94. 1994;354-370 Gustav Fischer, Stuttgart, Germany.
47. Staffeldt B., Kerb R.et al. Pharmacokinetics of hypericin and pseudohypericin after local intake of the Hypericum perforatum extract LI160 in healthy volunteers. J Geriatr Psych Neurol. 7(Suppl 1):1994;S47-S53.
48. Cott J.M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsych. 30:1997;108-112.
49. Cott J.M., Misra R. Medicinal plants: a potential source of new psychotherapeutic drugs. Kanba S., Richelson S.E. New drug development from herbal medicines in neuropharmacology. vol 5:1998;Brunner/Mazel, New York.
50. Muller W. Effect of Hypericum extract on the suppression of serotonin receptors. J Geriat Psych Neurol. 7:1994;S63-S64.
51. Linde K., Ramirez C.D.et al. St. John's wort for depression - an overview and meta-analysis of randomized clinical trials. BMJ. 313:1996;253-258.
52. McGuffin M., Hobbs C.et al. Botanical safety hand-book. American Herbal Products Association. 1997;CRC Press, Boca Raton.
53. Czekalla J., Gastpar M.et al. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry. 30(Suppl 2):1997;86-88.
54. Bahrke M.S., Morgan W.P. Evaluation of ergogenic properties of ginseng. Sports Med. 18:1994;229-248.
55. Shan Y., Xu X.H., Jiang U.P. Effects of ginsenosides on myocardial ischemia/reperfusion damage in open heart surgery patients. Chung Hua I Hsueh Tsa Chih. 74:1994;626-628.
56. Rimar S., Lee-Mengel M., Gillis C.N. Pulmonary protective and vasodilator effects of a standardized panax ginseng preparation following artificial gastric digestion. Pulm Pharmacol. 9:1996;205-209.
57. Ng T.B., Li W.W., Yeung H.W. Effects of ginsenosides, lectins, and momordica charantia insulin like peptide on corticosterone production by isolated rat adrenal cells. J Ethnopharm. 21:1987;21-29.
58. Jie Y.H., Cammisuli S.et al. Immunomodulatory effects of panax ginseng: CA Meyer in the mouse. Agents Actions Suppl. 15:1984;386-391.
59. Sotaniemi E.A., Haapakkoski E.et al. Ginseng therapy in non-insulin dependent diabetic patients. Diabetes Care. 18:1995;1373-1375.
60. Yokozawa T., Kobayashi T.et al. Studies on the mechanism of hypoglycemic activity of ginsenoside-Rb2 in streptozotocin-diabetic rats. Chem Pharm Bull. 33:1985;869-872.
61. Oshima Y., Kkonno C., Hikono H. Isolation and hypoglycemic activity of panaxans I, J, K and L, glycans of panax ginseng roots. J Ethnopharm. 14:1985;255-259.
62. Konno C., Murakami M.et al. Isolation and hypoglycemic activity of panaxans Q, R, S, R and U: glycans of panax ginseng roots. J Ethnopharm. 14:1985;69-74.
63. Konno C., Sugiyama K.et al. Isolation and hypoglycemic activity of panaxans A, B, C, D and E glycans of panax ginseng roots. Planta Med. 50:1984;436-438.
64. Tokmoda M., Shimada K.et al. Partial structure of panax A: a hypoglycemic glycan of panax ginseng roots. Planta Med. 50:1984;436-438.
65. Baldwin C.A. What pharmacists should know about ginseng. Pharm J. 237:1986;583-586.
66. Hammond T.G., Whitworth J.A. Adverse reactions to ginseng [letter]. Med J Aust. 1:1981;492.
67. Dega H., Laporte J.et al. Ginseng a cause of Steven-Johnson Syndrome [letter]? Lancet. 347:1996;1344.
68. Greenspan E.M. Ginseng and vaginal bleeding [letter]. JAMA. 249:1983;2018.
69. Hopkins M.P., Androff L.et al. Ginseng face cream and unexpected vaginal bleeding. Am J Obs Gyn. 159:1988;1121-1122.
70. Palmer B.V., Montgomery A.C.et al. Ginseng and mastalgia. BMJ. 1:1978;1284.
71. O'Hara M.A., Keifer D., Farrell K., Kemper K. A review of 12 commonly used medicinal herbs. Arch Fam Med. 7(6):1998;523-536.
72. Janetzky K., Morreale A.P. Probable interactions between warfarin and ginseng. Am J Health Syst Pharm. 54:1997;692-693.
73. Kuo S.C., Teng C.M.et al. Antiplatelet components in panax ginseng. Planta Med. 56:1990;164-167.
74. Shader R.I., Greenblatt D.J. Phenelzine and the dream machine-ramblings and reflections [editorial]. J Clin Psychopharmacol. 5:1985;65.
75. Jones B.D., Runikis A.M. Interactions of ginseng with phenelzine. J Clin Psychopharm. 7:1987;201-202.
76. Norton S.A. Herbal medicines in Hawaii from tradition to convention. Hawaii Med J. 57(1):1998;382-386.
77. Norton S.A., Ruze P. Kava dermapathy. J Am Acad Derm. 31(1):1994;89-97.
78. Garner L.F., Klinger J.D. Some visual effects caused by the beverage kava. J Ethnopharm. 13(3):1985;307-311.
79. Jamieson D.D., Duffield P.H. The antinociceptive actions of kava components in mice. Clin Exp Pharm Physio. 17(7):1990;495-507.
80. Singh Y.N. Effects of kava on neuromuscular transmission and muscular contractility. J Ethnopharm. 7(3):1983;267-276.
81. Seitz U., Schule A., Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med. 63(6):1997;548-549.
82. Jamieson D.D., Duffield P.H. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharm Physiol. 17(7):1990;509-514.
83. Gruenwald J., Brendler T.et al. PDR for herbal medicines. 1st edition:1998;1043-1045 Medical Economics Company, Montvale, New Jersey.
84. Piper methysticum. (Kava Kava). Altern Med Rev. 3(6):1998;458-460.
85. Murphy J., Heptinstall S.et al. Randomized double-blind, placebo-controlled trial of feverfew in migrane prevention. Lancet. 2:1988;189-192.
86. De Weerdt C., Bootsma H., Hendricks H. Herbal medicines in migrane prevention: randomized double-blind, placebo-controlled crossover trial of a feverfew preparation. Physomed. 3:1996;225-230.
87. Marles R.J., Kaminski J.et al. A bioassay of inhibition of serotonin release from bovine platelets. J Nat Prod. 55(8):1992;1044-1056.
88. Fozard J.R. 5-Hydroxytryptamine in the pathophysiology of migrane. Bevan J.A. Vascular neuroeffector mechanisms. 1985;321-328 Elsevier, The Netherlands.
89. Makheja A.N., Bailey J.M. A platelet phospholipase inhibitor from the medicinal herb feverfew (tanacatum parthenium). Proostaglandins Leukot Med. 8:1982;653-660.
90. Collier J.O.H., Butt N.M.et al. Extract of feverfew inhibits prostaglandins biosynthesis. Lancet. 2:1980;922-923.
91. US Pharmacopoeia: US Pharmacopoeia Consumer Information Drug information. Feverfew. 1998;The United States Pharmacopeial Convention Inc. Rockville, MD.
92. Baldwin C.A., Anderson L.A.et al. What pharmacists should know about feverfew. J Pharm Pharmacol. 239:1987;237-238.
93. Heptinstall S., Groenwegen W.A.et al. Extracts of feverfew may inhibit platelet behavior neutralization of sulphydryl groups. J Pharm Pharmacol. 39:1987;459-465.
94. Makheja A.N., Bailey J. The active principle in feverfew [letter]. Lancet. 2:1981;1054.
95. Foster S. Herbs for your health. 1996;37-38 Interweave Press, Loveland, CO.
96. Tinkleman D.G., Avner S.E. Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects. JAMA. 237(6):1977;553-557.
97. Gurley B.J., Gardner S.F.et al. Ephedrine pharmacokinetics after ingestion of nutritional supplements containing ephedra sinica (ma huang). Ther Drug Monit. 20(4):1998;439-445.
98. Morbid Mortality Weekly Report. 45(32):Aug 16, 1996;689-693.
99. Gruenwald J., Brendler T.et al. PDR for herbal medicines. 1st edition:1998;826-827 Medical Economics Co. Montvale, New Jersey.
100. Ping-Heng T., An-Kuo C., Jyh-Shyan P. Accidental shock during epidural anesthesia in a patient with NSAID-induced hyporeninemic hypoaldosteronism. J Clin Anesth. 9:1997;424-427.
101. Jian H.S. Hemodynamic actions of Huatuo reconstruction pill on anesthetized animals. Adv Exp Med Biol. 363:1995;183-187.
102. Ellenhorn M.J., Schonwald S.et al. Medical toxicology: diagnosis and treatment of human poisoning. 2nd edition:1997;Williams & Wilkins, Baltimore, MD.
103. Vanherwegham J.L., Depierreux M.et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 341:1993;387-391.
104. Abt A.B., Oh J.Y.et al. Chinese herbal medicine induced acute renal failure. Arch Intern Med. 155:1995;211-212.
105. Vanhaelen M., Vanhaelen-Fastre R.et al. Identification of aristolochic acid in Chinese herbs [letter]. Lancet. 343:1994;174.
106. Van Ypersele de Strihou C., Vanherweghem J.L. The tragic paradigm of Chinese herbs nephropathy [editorial]. Nephrol Dia Transplant. 10:1995;157-160.
107. Gordon D.W., Rosenthal G.et al. Chaparral ingestion: the broadening spectrum of liver injury caused by herbal medications. JAMA. 273:1995;489-490.
108. Kaye A.D., Sabar R., Clarke R., Vig S., Hofbauer R., Kaye A.M. Herbal medications and anesthetics. A review on current concepts. Am J Anesthesiol. 27(7):2000;405-407.
109. Sabar R., Kaye A.D., Frost E. Preoperative considerations for the patient on herbal medicines. Heart Dis. 2:2001;1-11.
110. Kaye A.D., Clarke R., Sabar R., Kaye A.M. Herbal medications survey. J Clin Anesth. 12:2000;468-471.
111. Kaye A.D., Kaye A.M., Hegazi A., Sabar R., Deaton B., Powell J.et al. Nutraceuticals: potential roles and potential risks for pain management. Pain Practice. 2:2002;122-128.